Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab

Rheumatology (United Kingdom)

Volumn 56, Issue 2, 2017, Pages 247-254

  Aggarwal, Rohit ^a   Loganathan, Priyadarshini ^a   Koontz, Diane ^a   Qi, Zengbiao ^a   Reed, Ann M ^b   Oddis, Chester V ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cell depletion; Cutaneous; Dermatomyositis; Juvenile dermatomyositis; Rituximab

Indexed keywords

PLACEBO; RITUXIMAB; ANTIRHEUMATIC AGENT;

ADULT; ADULT DERMATOMYOSITIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; ERYTHEMA; ERYTHRODERMA; FEMALE; HUMAN; HUMORAL IMMUNE DEFICIENCY; JUVENILE DERMATOMYOSITIS; MAJOR CLINICAL STUDY; MALE; PAPULE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SKIN MANIFESTATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ADOLESCENT; CHILD; DERMATOMYOSITIS; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PATHOLOGY; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; CHILD; DERMATOMYOSITIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RITUXIMAB; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85014138357     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew396     Document Type: Article

References (20)

1. Cooper MA, Willingham DL, Brown DE et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007;56:3107-11.
2. Dinh HV, McCormack C, Hall S et al. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol 2007;56:148-53.
3. Holzer U, van Royen-Kerkhof A, van der Torre P et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol 2010;39:88-92.
4. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005;52:601-7.
5. Tzaribachev N, Koetter I, Kuemmerle-Deschner JB et al. Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 2009;2:6609.
6. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007;143:763-7.
7. Chiu YE, Co DO. Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. Pediatr Dermatol 2011;28:357-67.
8. Oddis CV, Reed AM, Aggarwal R et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24.
9. Sultan SM, Allen E, Oddis CV et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 2008;58:3593-9.
10. Isenberg DA, Allen E, Farewell V et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology 2004;43:49-54.
11. Pilkington C, Murray K, Isenberg I et al. Development of disease activity and damage indices for myositis. Initial testing of four tools in juvenile dermatomyositis. Arthritis Rheum 2001;44:S294.
12. Rider L, Schiffenbauer A, Villalba M et al. Extramuscular disease activity is frequent in adult and juvenile idiopathic inflammatory myopathies (IIM) and does not correlate with other myositis activity measures. Arthritis Rheum 2002;46:S612-3.
13. Sultan SM, Allen E, Cooper K et al. Inter-rater reliability of two disease activity and damage assessment tools in patients with idiopathic inflammatory myopathy-report of 105 patients. Arthritis Rheum 2004;50:S668.
14. Rider LG, Giannini EH, Brunner HI et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004;50:2281-90.
15. http://www.niehs.nih.gov/research/resources/imacs/ diseaseactivity.
16. Khanna S, Reed AM. Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve 2010;41:581-92.
17. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
18. Santmyire-Rosenberger B, Dugan EM. Skin involvement in dermatomyositis. Curr Opin Rheumatol 2003;15:714-22.
19. Krystufková O, Vallerskog T, Helmers SB et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 2009;68:836-43.
20. Baek A, Park HJ, Na SJ et al. The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol 2012;249:96-100.